Previous 10 | Next 10 |
home / stock / akblf / akblf news
Primary and all key secondary confirmatory endpoints w ere met, with a n improvement in the total combined allergic rhinitis score (TCRS) of 22 % compared to placebo (primary endpoint) . Results were highly statistically sign...
Revenue up 7%, full-year outlook maintained (unaudited) ALK’s overall results in Q1 2023 were largely as expected, with 7% organic revenue growth in local currencies and increased operating profit with an EBIT margin of 18%. Combined SCIT and SLIT-drops sales exceeded expectation...
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 23 March 2023 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the B...
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that Claus Steensen Sølje will take up the position as Executive Vice President, Chief Financial Officer (CFO) and member of the Board of Management no later than 1 June 2023. He succeeds Søren Jelert, whose decision to leave ...
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that its Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (AIT) tablet has been accepted for review by the National Medical Products Administration (NMPA) in China. The BLA, for treatmen...
ALK's ( ALKB:DC / OMX: ALK B / AKBLF ) Board of Directors has approved the company’s 2022 annual report (ESEF-version ALK-2022-12-31-en attached). Following a solid Q4, full-year results exceeded initial expectations and were in line with the most recent outlook. ALK expects to con...
U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents PR Newswire – ODACTRA is now indicated to treat house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, in persons ...
ALK-Abelló A/S press release (OTCPK:AKBLF): Q1 GAAP EPS of $0.70. Revenue of $1.16B (+13.7% Y/Y). Outlook for 2022, ALK is maintaining its full-year outlook: Revenue is still expected to grow 8-12% in local currencies with tablet sales up by ~20%; EBITDA is still expected to increa...
ALK-Abelló A/S press release (OTCPK:AKBLF): Q4 EBITDA more than doubled to DKK136M vs. DKK64M, reflecting higher sales, improved gross margins and a modest increase in capacity costs. Revenue of DKK 1.1B (+11.0% Y/Y). For 2022, ALK expects revenue growth of 8-12% and a further impro...
The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma - Results from ALK-sponsored REACT (REAl-world effeCTtiveness of allergy immunotherapy) study have ...
News, Short Squeeze, Breakout and More Instantly...
Alk-Abello A/S Company Name:
AKBLF Stock Symbol:
OTCMKTS Market:
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the Board of Directors has adopted a new corporate strategy (Allergy + ) and 2028 financial ambitions. Allergy + aims to further strengthen ALK’s leadership in allergy immunotherapy, establishing a leading position...
Company release No. 11/2024 ALK delivers 10 % organic revenue growth with operating profit up 41 % in Q1 and upgrades outlook The growth in ALK's overall sales was primarily driven by the European tablet sales, which were boosted by the inflow of new patients and improved ...
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the B...